McIlrath & Eck’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $248K | Hold |
1,138
| – | – | 0.02% | 220 |
|
|
2025
Q4 | $260K | Buy |
1,138
+375
| +49% | +$85.4K | 0.02% | 130 |
|
|
2025
Q3 | $177K | Sell |
763
-51
| -6% | -$10.4K | 0.02% | 158 |
|
|
2025
Q2 | $151K | Hold |
814
| – | – | 0.02% | 157 |
|
|
2025
Q1 | $171K | Hold |
814
| – | – | 0.02% | 142 |
|
|
2024
Q4 | $145K | Sell |
814
-12
| -1% | -$2.21K | 0.02% | 143 |
|
|
2024
Q3 | $163K | Sell |
826
-153
| -16% | -$28.6K | 0.02% | 139 |
|
|
2024
Q2 | $168K | Buy |
979
+63
| +7% | +$10.4K | 0.02% | 128 |
|
|
2024
Q1 | $167K | Hold |
916
| – | – | 0.03% | 126 |
|
|
2023
Q4 | $142K | Hold |
916
| – | – | 0.03% | 134 |
|
|
2023
Q3 | $137K | Sell |
916
-1,687
| -65% | -$248K | 0.03% | 138 |
|
|
2023
Q2 | $351K | Sell |
2,603
-221
| -8% | -$32.4K | 0.07% | 83 |
|
|
2023
Q1 | $450K | Buy |
2,824
+424
| +18% | +$64.8K | 0.11% | 59 |
|
|
2022
Q4 | $388K | Sell |
2,400
-805
| -25% | -$123K | 0.1% | 65 |
|
|
2022
Q3 | $430K | Buy |
3,205
+134
| +4% | +$19.2K | 0.12% | 55 |
|
|
2022
Q2 | $470K | Sell |
3,071
-198
| -6% | -$30.3K | 0.15% | 43 |
|
|
2022
Q1 | $530K | Buy |
3,269
+122
| +4% | +$17.7K | 0.15% | 40 |
|
|
2021
Q4 | $426K | Sell |
3,147
-457
| -13% | -$54K | 0.12% | 50 |
|
|
2021
Q3 | $389K | Buy |
3,604
+787
| +28% | +$89.9K | 0.12% | 49 |
|
|
2021
Q2 | $317K | Sell |
2,817
-351
| -11% | -$39.5K | 0.1% | 57 |
|
|
2021
Q1 | $343K | Sell |
3,168
-466
| -13% | -$49.8K | 0.12% | 46 |
|
|
2020
Q4 | $389K | Buy |
3,634
+561
| +18% | +$53.9K | 0.14% | 41 |
|
|
2020
Q3 | $269K | Hold |
3,073
| – | – | 0.12% | 41 |
|
|
2020
Q2 | $302K | Buy |
3,073
+722
| +31% | +$63.6K | 0.14% | 40 |
|
|
2020
Q1 | $179K | Sell |
2,351
-381
| -14% | -$32.5K | 0.1% | 44 |
|
|
2019
Q4 | $242K | Buy |
2,732
+791
| +41% | +$65.7K | 0.12% | 46 |
|
|
2019
Q3 | $147K | Sell |
1,941
-294
| -13% | -$20.2K | 0.08% | 48 |
|
|
2019
Q2 | $180K | Hold |
2,235
| – | – | 0.1% | 48 |
|
|
2019
Q1 | $180K | Sell |
2,235
-67
| -3% | -$5.48K | 0.1% | 48 |
|
|
2018
Q4 | $212K | Buy |
2,302
+156
| +7% | +$13.7K | 0.14% | 40 |
|
|
2018
Q3 | $203K | Sell |
2,146
-363
| -14% | -$34.4K | 0.12% | 45 |
|
|
2018
Q2 | $232K | Buy |
2,509
+150
| +6% | +$14.6K | 0.14% | 40 |
|
|
2018
Q1 | $223K | Sell |
2,359
-1,436
| -38% | -$158K | 0.13% | 43 |
|
|
2017
Q4 | $367K | Buy |
+3,795
| New | +$358K | 0.22% | 30 |
|
Other funds holding ABBV
McIlrath & Eck's ABBV Position: Q1 2026 in Review
McIlrath & Eck held its AbbVie (ABBV) position steady in Q1 2026 at 1,138 shares worth $248K. The position accounts for 0.02% of the portfolio, ranked #220.
McIlrath & Eck first reported a position in ABBV in Q4 2017 and has held it in 34 quarters since. The position peaked at $530K in Q1 2022. 4,097 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- McIlrath & Eck held 1,138 shares of AbbVie worth $248K as of Q1 2026.
- McIlrath & Eck left its AbbVie share count unchanged in Q1 2026.
- AbbVie made up 0.02% of McIlrath & Eck's portfolio in Q1 2026, its #220 holding.
- McIlrath & Eck first reported a position in AbbVie in Q4 2017 and has held it in 34 quarters since.
- McIlrath & Eck's AbbVie position peaked at $530K in Q1 2022.
- 4,097 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on McIlrath & Eck's 13F filing for Q1 2026, filed 19 May 2026.